Jun 06, 2018 — Accelerate Diagnostics, Inc. announced today it will host symposia on the clinical opportunities of integrating fast, phenotypic susceptibility testing into antimicrobial stewardship programs and its impact on the management of patients with bacteremia at the American Society of Microbiologist Microbe 2018 forum in Atlanta, Georgia.
Accelerate Diagnostics reports Q1 2018 financial results
May 10, 2018 — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up 51% from the prior year, and reported signed agreements for 345 instruments.
Accelerate Diagnostics shares performance data at AMMI/CACMID
May 03, 2018 — Accelerate Diagnostics, Inc. announced today that performance data will be presented during the Association of Medical Microbiology and Infectious Disease Canada/Canadian Association for Clinical Microbiology and Infectious Disease 2018 congress in Vancouver, Canada, May 2-5 at the Sheraton Vancouver Wall Centre. See the company’s press release for additional details.
Hospital Universitario De La Princesa in Madrid, Spain adopts The Accelerate Pheno™ system
Apr 23, 2018 — Hospital Universitario De La Princesa in Madrid, Spain adopts The Accelerate Pheno™ system to shorten adaptation treatment for severe sepsis by 28 hours as compared to the hospital’s conventional system. See the company’s press release for additional details.
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
Want to hear when we announce our next event? Stay up to date with Accelerate by joining our mailing list.Sign up today
June 7–11, 2018
May 9–12, 2018
May 2–5, 2018
April 21–24, 2018
February 25 - 27, 2018
San Antonio, TX
15 - 16 February 2018
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.